Search the Newsreel

(BVFL) Movement Within Algorithmic Entry Frameworks

This article provides an algorithmic analysis for Bv Financial Inc. (NASDAQ: BVFL), highlighting a near-term strong sentiment influencing a mid-term neutrality towards a long-term positive bias. It details several institutional trading strategies including position, momentum, and risk hedging, alongside a multi-timeframe signal analysis and …

Liquidity Mapping Around (BV) Price Events

This article analyzes Brightview Holdings Inc. (NYSE: BV) using AI models to provide liquidity mapping and trading strategies. Key findings indicate a neutral sentiment, with resistance being tested, and offers specific position, momentum, and risk-hedging strategies for different risk profiles. The analysis highlights an …

AbbVie Announces Availability of ELAHERE® (mirvetuximab soravtansine) in Singapore for the Treatment of Platinum-Resistant Ovarian Cancer

AbbVie has announced the availability of ELAHERE (mirvetuximab soravtansine) in Singapore for treating platinum-resistant ovarian cancer. This antibody-drug conjugate (ADC) is the first and only one approved for patients with FRα-positive high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have undergone …

ABVC BioPharma (ABVC) to vote on 2026 equity plan and Taiwan land-share issuance

ABVC BioPharma is holding a virtual special shareholder meeting on September 18, 2026, to vote on three key proposals. These include approving a new 2026 Equity Incentive Plan, ratifying equity awards granted after February 16, 2026, and authorizing the issuance of up to 6,638,591 …

AbbVie Inc (ABBV) director adds stock-equivalent units after 25.5% 12-week rise

The insider acquisition lands with the biopharma stock still in an active weekly trend, though latest volume ran below its 13-week average.

Botox Maker Tops Buy Point, But Here Comes The Earnings Report

AbbVie closed above the 230.47 buy point from a cup-with-handle base on June 23 and has climbed 15% from there. The previous day, the stock jumped more than 6% after AbbVie announced it agreed to acquire Apogee Therapeutics. The $10.9 billion deal would strengthen …

3 Major Reasons for Investors to Buy AbbVie Stock Before July 31st

Quick Read ABBV trades at a PEG of 0.43 with a beta of just 0.28, while Skyrizi and Rinvoq combined for $6.6 billion in Q1 revenue. ABBV's 164% five-year gain dwarfs Pfizer's negative 23% return, while Merck still faces a 2028 Keytruda patent cliff …

Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?

AbbVie ABBV is set to report second-quarter 2026 earnings on July 31, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter's sales is pinned at $16.81 billion, while earnings per share (EPS) are estimated at $3.66. Both metrics indicate an increase …

ProQR Therapeutics (NASDAQ:PRQR) Director Bart Filius Buys 150,000 Shares

ProQR Therapeutics Director Bart Filius increased his stake in the company by purchasing 150,000 shares for $258,000, doubling his total ownership to 300,000 shares. This follows a similar purchase in June. Shares of ProQR (NASDAQ:PRQR) traded down slightly and the company, valued at $181.75 …

AbbVie Inc Stock (ABBV) Moved Up by 3.35% on Jul 28: A Full Analysis

AbbVie Inc (ABBV) saw its stock rise by 3.35% on July 28, outperforming the Pharmaceuticals & Medical Research sector. This strong performance was attributed to robust second-quarter earnings, significant growth in its immunology drugs Skyrizi and Rinvoq, and positive late-stage clinical trial data in …

ATAI Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of AtaiBeckley to Eli Lilly

MONSEY, N.Y., July 28, 2026 (GLOBE NEWSWIRE) -- The Monsey law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of AtaiBeckley, Inc. (Nasdaq: ATAI) (“AtaiBeckley”) to Eli Lilly and Company (“Lilly”), pursuant to which AtaiBeckley shareholders will receive …

Barclays Adjusts AbbVie PT to $300 From $275, Maintains Overweight Rating

Barclays has increased its price target for AbbVie (ABBV) to $300 from $275, while reiterating an Overweight rating on the stock. The adjustment reflects an updated outlook from the analytical firm regarding the pharmaceutical company's future performance. AbbVie specializes in therapeutic drug research and …

Elmind Capital LP Makes New Investment in DBV Technologies S.A. $DBVT

Goldman Sachs uncovers key AbbVie stock signals before earnings

BrightView (BV) Projected to Announce Quarterly Earnings on Tuesday

BBVA Banco Frances S.A. (NYSE:BBAR) Given Consensus Rating of "Moderate Buy" by Brokerages

ABVC Biopharma Inc (ABVC) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of ABVC Biopharma Inc's (ABVC) dividend history and stock split events. It indicates that the company has not distributed any dividends in the past five years and lists several merger-related stock splits that occurred on July 24, 2023, each …

ABVC Biopharma Inc (ABVC) Cash Flow

This article provides a detailed cash flow statement for ABVC Biopharma Inc (ABVC), encompassing quarterly and annual data for operating, investing, and financing activities. It also includes frequently asked questions explaining different types of cash flow and their significance for the company's financial health. …

New Century Logistics (BVI) Limited Revenue Breakdown – NASDAQ:NCEW

ABVC Biopharma Inc (ABVC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for ABVC Biopharma Inc (ABVC), detailing its business segments, regional revenue, and profit contribution. However, the data has not been disclosed by the company yet, indicating a lack of publicly available information on these specific financial …

Eli Lilly (NYSE: LLY) reports 21.99M-share beneficial stake in ProQR Therapeutics

Eli Lilly and Company has reported a beneficial ownership of 21,995,880 ordinary shares in ProQR Therapeutics N.V., representing a 15.6% stake. This information was disclosed in an amended Schedule 13G/A filing, indicating that Eli Lilly holds sole voting and dispositive power over all these …

ABVC Biopharma Inc (ABVC) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of ABVC Biopharma Inc (ABVC), noting its current stock price momentum score is 5.98, ranking 29th in its industry. The stock is trading between a resistance level of 1.79 and a support level of 0.60, suggesting suitability for …

Should You Buy AbbVie Stock Hand Over Fist Before July 31?

Before the market opens on July 31, AbbVie (NYSE: ABBV) will report second-quarter results, hoping to build on the momentum from its Q1 earnings beat. As the key catalyst behind last quarter's performance remains in motion, the same could repeat when second-quarter results hit …

BV Financial Inc (BVFL) Income Statement

This article presents the income statement for BV Financial Inc (BVFL), offering both quarterly and annual financial insights. It details key metrics such as total revenue, operating expenses, operating profit, income before tax, income tax, income after tax, net income attributable to controlling interests …

Brightview Holdings Inc (BV) Income Statement

This article provides a detailed quarterly and annual income statement for Brightview Holdings Inc (BV), offering insights into its financial performance and operational efficiency. It presents key financial metrics such as total revenue, cost of revenue, operating expenses, operating profit, net income, and earnings …

ABVC Biopharma Inc (ABVC) Institutional Confidence

The article analyzes the institutional confidence in ABVC Biopharma Inc (ABVC), noting its current institutional shareholding score of 3.00, placing it 192nd in its industry. Institutional ownership stands at 3.41%, an increase of 1.88% quarter-over-quarter. James Simons is identified as the largest institutional shareholder, …

BV Financial Inc (BVFL) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides dividend and stock split information for BV Financial Inc (BVFL). It indicates that BVFL has distributed $0.00 in dividends over the past five years and currently shows no dividend data available. The page also displays current stock metrics such as market …

Pharvaris NV (PHVS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Pharvaris NV (PHVS), listing major shareholders like General Atlantic LLC and Fidelity Management & Research Company LLC. It breaks down shareholder types, including private equity and hedge funds, and provides a quarterly overview of institutional shareholdings and …

Brightview Holdings Inc (BV) Cash Flow

This article presents the quarterly and annual cash flow statements for Brightview Holdings Inc (BV), covering operating, investing, and financing activities. It provides detailed financial data from FY2018Q1 to FY2026Q2 for various cash flow components, including net income, operating gains/losses, capital expenditures, and debt …

Dbv Technologies SA (DBVT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Dbv Technologies SA (DBVT), including stock price information and market capitalization. However, it explicitly states that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. Consequently, …

Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chapter

Sarepta Therapeutics has appointed Michael Severino, former vice chairman at AbbVie and CEO of Tessera Therapeutics, as its new chief executive, effective Tuesday. Severino replaces Doug Ingram, who is retiring due to family health issues. Severino will face the challenge of navigating commercial realities …

Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO

Sarepta Therapeutics has appointed Michael Severino, an executive with experience at AbbVie and Amgen and most recently Tessera Therapeutics, as its new CEO, effective July 28. Severino faces the challenge of turning around Sarepta's fortunes, as the company has lost significant market value over …

Pharvaris NV (PHVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article discusses the revenue breakdown for Pharvaris NV (PHVS), indicating that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. Despite providing a stock overview with current trading figures and market cap, specific financial …

Sarepta names former AbbVie R&D exec Michael Severino as next CEO

Sarepta Therapeutics has appointed Michael Severino, formerly of Tessera Therapeutics and AbbVie, as its new CEO, succeeding Doug Ingram. Severino takes the helm at a critical juncture as Sarepta awaits two key FDA decisions for its Duchenne muscular dystrophy drugs, Amondys 45 and Vyondys …

AbbVie stock hits all-time high of 261.71 USD

AbbVie Inc. (ABBV) stock has reached a new all-time high of $261.71, reflecting a 40.53% total return over the past year. Despite being considered slightly overvalued by InvestingPro analysis, the company demonstrates strong financial health with 9.5% revenue growth. Upcoming earnings on July 31st …

Is AbbVie Stock a Buy After Its $10.9 Billion Apogee Bet

AbbVie (ABBV) recently acquired Apogee Therapeutics for $10.9 billion, a move that is expected to dilute adjusted EPS until 2032 but aims for a "mega blockbuster" drug, zumilokibart, targeting over $10 billion in peak sales. Despite the near-term dilution, AbbVie stock has largely recovered …